These studies suggested that C5aR1 activation resulted in deleterious consequences at the early phase of ischemic brain injury, raising an opportunity to use specific C5aR1 antagonists to modulate complement activation and attenuate acute ischemic brain injury in humans. Here, C5AR1 is linked to brain injury.